Rexulti (brexpiprazole) Letter of Medical Necessity
Rexulti (brexpiprazole) PA criteria differ by indication. For dementia agitation, the boxed warning acknowledgment and behavioral non-pharmacologic trial documentation are critical.
FDA-Approved Indications
- ● schizophrenia
- ● adjunctive treatment of major depressive disorder
- ● agitation in Alzheimer's dementia
Why Rexulti Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Generic aripiprazole preferred
- 2. Indication not specified
- 3. Black box warning acknowledgment for dementia indication
What to Include in a Rexulti Letter of Medical Necessity
Document indication, prior treatments, severity, and (for dementia) non-pharmacologic intervention trials and family discussion of risks.
Key clinical evidence to cite:
- ✓ Pyxis, Vega, MERIT, Studies 213/214/283/331
Relevant guidelines:
- 📖 APA Schizophrenia Guideline
- 📖 APA Alzheimer Dementia Guideline
Rexulti Prior Authorization Criteria
Standard criteria across major US payers for Rexulti. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Documented failure or contraindication to formulary alternatives
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Rexulti
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Rexulti Prior Authorization FAQ
Why was my Rexulti prior authorization denied?
The most common denial reasons for Rexulti are: Generic aripiprazole preferred; Indication not specified; Black box warning acknowledgment for dementia indication.
What should a Rexulti Letter of Medical Necessity include?
Document indication, prior treatments, severity, and (for dementia) non-pharmacologic intervention trials and family discussion of risks.
Which payers cover Rexulti?
Rexulti is covered by major US payers including UnitedHealthcare, Aetna, Cigna, CVS Caremark, Medicare Part D, though formulary tier and prior authorization criteria vary.